Lynparza has the potential to offer a new treatment option for patients with metastatic breast cancer. AstraZeneca and Merck & Co., have announced that the US Food and Drug Administration
Tag "Merck & Co"
Merck & Co has terminated a Phase II/III trial testing its investigational medicine verubecestat in patients with mild to moderate Alzheimer’s disease. The move came after an external data monitoring
Advertisements
